v3.25.4
ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended 36 Months Ended
May 13, 2025
USD ($)
$ / shares
Mar. 18, 2024
USD ($)
$ / shares
Feb. 26, 2024
USD ($)
$ / shares
Jan. 23, 2024
USD ($)
right
$ / shares
Dec. 31, 2025
USD ($)
Oct. 31, 2023
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2026
Feb. 28, 2025
USD ($)
Business Combination [Line Items]                      
Royalty Income             $ 1,129 $ 1,104 $ 862    
Keytruda Royalties                      
Business Combination [Line Items]                      
Sales payable from alliance partner                 6.50%    
Keytruda Royalties | Forecast                      
Business Combination [Line Items]                      
Sales payable from alliance partner                   2.50%  
Bristol-Myers Squibb | Keytruda Royalties | Forecast | Subsequent Event                      
Business Combination [Line Items]                      
Payment and royalty allocation                   75.00%  
Ono | Keytruda Royalties | Forecast | Subsequent Event                      
Business Combination [Line Items]                      
Payment and royalty allocation                   25.00%  
LianBio Co. Ltd. | Mavacamten Rights                      
Business Combination [Line Items]                      
Payments for asset acquisitions           $ 445          
Payments to acquire rights           $ 350          
Philochem | OncoACP3 Global Exclusive License                      
Business Combination [Line Items]                      
License and other arrangements upfront payments         $ 350   350        
Contingent and regulatory milestone payments, maximum aggregate         1,000   1,000        
BioArctic | PyroGlutamate-amyloid-beta Antibody Program Global Exclusive License                      
Business Combination [Line Items]                      
License and other arrangements upfront payments         100   100        
Contingent and regulatory milestone payments, maximum aggregate                     $ 1,300
Merck | Reblozyl License                      
Business Combination [Line Items]                      
Royalty expense             $ 505 386 $ 208    
Merck | Reblozyl License | Minimum                      
Business Combination [Line Items]                      
Percentage of net sales payable to alliance partner             20.00%        
Merck | Reblozyl License | Maximum                      
Business Combination [Line Items]                      
Percentage of net sales payable to alliance partner             24.00%        
Merck | Winrevair* License                      
Business Combination [Line Items]                      
Percentage of net sales payable to alliance partner             22.00%        
Proceeds from royalties earned             $ 289 $ 107      
Diabetes business - royalties                      
Business Combination [Line Items]                      
Percentage of net sales payable to alliance partner             14.00% 15.00% 15.00%    
Royalty Income             $ 1,121 $ 1,097 $ 862    
Diabetes business - royalties | Supply Agreements                      
Business Combination [Line Items]                      
Royalty Income             1,200 1,200 960    
Diabetes business - royalties | Amylin, Onglyza, and Farxiga                      
Business Combination [Line Items]                      
Business sale royalty expense             88 96 $ 98    
RayzeBio                      
Business Combination [Line Items]                      
Business acquisition, share price (in usd per share) | $ / shares     $ 62.50                
Acquisitions (Note 4)     $ 4,147                
Total consideration allocated     3,600                
RayzeBio | Unvested Equity Awards                      
Business Combination [Line Items]                      
Acquisitions (Note 4)     $ 274                
RayzeBio | Selling, general and administrative | Unvested Equity Awards                      
Business Combination [Line Items]                      
Acquisitions (Note 4)               159      
RayzeBio | Research and development | Unvested Equity Awards                      
Business Combination [Line Items]                      
Acquisitions (Note 4)               115      
Mirati Therapeutics                      
Business Combination [Line Items]                      
Business acquisition, share price (in usd per share) | $ / shares       $ 58.00              
Acquisitions (Note 4)       $ 4,801              
Total consideration allocated       $ 4,100              
Business combination, contingent value, number of rights received | right       1              
Business combination, contingent value, share price (in dollars per share) | $ / shares       $ 12.00              
Contingent consideration liability       $ 1,000              
Business combination, contingent value payout, period       7 years              
Mirati Therapeutics | Selling, general and administrative | Unvested Equity Awards                      
Business Combination [Line Items]                      
Acquisitions (Note 4)               60      
Mirati Therapeutics | Research and development | Unvested Equity Awards                      
Business Combination [Line Items]                      
Acquisitions (Note 4)               54      
Orbital Therapeutics                      
Business Combination [Line Items]                      
Total consideration allocated         1,700            
Payments for asset acquisitions, net of cash acquired         $ 1,500            
Orbital Therapeutics | Acquired IPRD                      
Business Combination [Line Items]                      
Payments for asset acquisitions             1,400        
Orbital Therapeutics | Selling, general and administrative | Unvested Equity Awards                      
Business Combination [Line Items]                      
Payments for asset acquisitions             55        
Orbital Therapeutics | Research and development | Unvested Equity Awards                      
Business Combination [Line Items]                      
Payments for asset acquisitions             $ 13        
2seventy bio                      
Business Combination [Line Items]                      
Asset acquisition, share price (in dollars per share) | $ / shares $ 5.00                    
Payments to acquire productive assets $ 287                    
Payments to acquire productive assets, net of cash acquired $ 114                    
Karuna                      
Business Combination [Line Items]                      
Total consideration allocated   $ 13,793                  
Payments for asset acquisitions, net of cash acquired   12,900                  
Payments for asset acquisitions   $ 14,027                  
Asset acquisition, share price (in dollars per share) | $ / shares   $ 330.00                  
Karuna | Acquired IPRD                      
Business Combination [Line Items]                      
Payments for asset acquisitions               12,100      
Karuna | Selling, general and administrative | Unvested Equity Awards                      
Business Combination [Line Items]                      
Payments for asset acquisitions               130      
Karuna | Research and development | Unvested Equity Awards                      
Business Combination [Line Items]                      
Payments for asset acquisitions               $ 159